MorphoSys Ag

Premium Company Profile

Publication Date	April 2008
Publisher	Datamonitor
Product Type	Report
Pages	45
ISBN Number	not applicable
Product Code	DAT11500

Price

£265.00
approximately: $521 | €337

PDF

PRINT £315 ($619 | €400)

Order above formats by FAX

Summary

Introduction

MorphoSys is a biotechnology company focused on the research and development of antibody drugs. The company's main technology platform includes HuCAL (Human Combinatorial Antibody Library), an innovative technology which allows rapid and automated production of high-affinity antibodies.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

The company currently has therapeutic and research alliances with the majority of the world's largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestone payments as well as royalties on any end products. MorphoSys derives its entire revenues from technology access fees and fees derived from research and development agreements primarily with companies such as Bayer, DuPont Pharmaceuticals, ImmunoGen, Hoffman La Roche and GPC Biotech.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .

Content

Overview
Catalyst
Summary
- Company Structure
- Company Overview and Key Facts
- Business Description
- History
- Locations and Subsidiaries
- Company Financials
- Stock Market Performance
- P&l
- Balance Sheet
- Cash Flow
- Business Segment Performance
- Geographic Segment Performance
- Products & Services
- Pipeline Products
- Ac Forecast Product Sales
- Competitors and Strategic Business Relationships
- Top Competitors
- Key Suppliers
- Key Clients
- Strategy
- Company View
- Corporate Strategy
- SWOT Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
- Overview
- Discovery and Product Development
- Manufacturing
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
- List of Key Employees
- Key Employee Biographies
- Financial and Operational Overview
- Financial and Operational Overview
- Appendix
- Ask The Analyst
- Datamonitor Consulting
- Disclaimer
Table of Figures
- Figure 1: Morphosys - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Figure 2: Morphosys - Revenue Breakdown, 2002-2006 ($ Mn)
- Figure 3: Morphosys - Key Strategic Revenues, 2006-2010 ($ Mn)
Table of Tables
- Table 1: Morphosys - Key Facts
- Table 2: Morphosys - Other Locations and Subsidiaries
- Table 3: Morphosys - Year-End Share Price and Market Capitalization, 2002-2006 (E)
- Table 4: Morphosys - Key Events Impacting Share Price Performance
- Table 5: Morphosys - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 6: Morphosys - Operating Cost Ratio Analysis, 2002-2006 (% of Total Revenues)
- Table 7: Morphosys - Balance Sheet, 2002-2006 ($ Mn)
- Table 8: Morphosys - Balance Sheet, 2002-2006 ($ Mn)
- Table 9: Morphosys - Revenue Breakdown, 2002-2006 ($ Mn)
- Table 10: Morphosys - Geographic Breakdown, 2002-2006 ($ Mn)
- Table 11: Morphosys - in-House Pipeline Products
- Table 12: Morhosys - Collaboration Pipeline Products
- Table 13: Morphosys - Forecast Sales, 2006-2010 ($ Mn)
- Table 14: Morphosys - Top Competitors
- Table 15: Morphosys - Key Suppliers
- Table 16: Morphosys - Key Clients
- Table 17: Morphosys - SWOT Analysis Summary
- Table 18: Morphosys - Value Chain Analysis
- Table 19: Morphosys - Scorecard
- Table 20: Morphosys - Key Employees
- Table 21: Morphosys - Financial and Operational Overview